Acute behavioral and Neurochemical Effects of Novel N-Benzyl-2-Phenylethylamine Derivatives in Adult Zebrafish.

Hallucinogenic drugs potently affect brain and behavior and have also recently emerged as potentially promising agents in pharmacotherapy. Complementing laboratory rodents, the zebrafish (Danio rerio) is a powerful animal model organism for screening neuroactive drugs, including hallucinogens. Here, we test a battery of ten novel N-benzyl-2-phenylethylamine (NBPEA) derivatives with the 2,4- and 3,4-dimethoxy substitutions in the phenethylamine moiety and the -OCH3, -OCF3, -F, -Cl, and -Br substitutions in the ortho position of the phenyl ring of the N-benzyl moiety, assessing their acute behavioral and neurochemical effects in the adult zebrafish. Overall, substitutions in the Overall, substitutions in the N-benzyl moiety modulate locomotion, and substitutions in the phenethylamine moiety alter zebrafish anxiety-like behavior, also affecting the brain serotonin and/or dopamine turnover. The 24H-NBOMe(F) and 34H-NBOMe(F) treatment also reduced zebrafish despair-like behavior. Computational analyses of zebrafish behavioral data by artificial intelligence identified several distinct clusters for these agents, including anxiogenic/hypolocomotor (24H-NBF, 24H-NBOMe, and 34H-NBF), behaviorally inert (34H-NBBr, 34H-NBCl, and 34H-NBOMe), anxiogenic/hallucinogenic-like (24H-NBBr, 24H-NBCl, and 24H-NBOMe(F)), and anxiolytic/hallucinogenic-like (34H-NBOMe(F)) drugs. Our computational analyses also revealed phenotypic similarity of the behavioral activity of some NBPEAs to that of selected conventional serotonergic and antiglutamatergic hallucinogens. In silico functional molecular activity modeling further supported the overlap of the drug targets for NBPEAs tested here and the conventional serotonergic and antiglutamatergic hallucinogens. Overall, these findings suggest potent neuroactive properties of several novel synthetic NBPEAs, detected in a sensitive in vivo vertebrate model system, the zebrafish, raising the possibility of their potential clinical use and abuse.

[1]  Ziyan Wang,et al.  Comparative analysis of molecular fingerprints in prediction of drug combination effects , 2021, Briefings Bioinform..

[2]  Georgii K. Galumov,et al.  Artificial intelligence-driven phenotyping of zebrafish psychoactive drug responses , 2021, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[3]  A. Kalueff,et al.  Modulation of behavioral and neurochemical responses of adult zebrafish by fluoxetine, eicosapentaenoic acid and lipopolysaccharide in the prolonged chronic unpredictable stress model , 2021, Scientific Reports.

[4]  M. Liechti,et al.  Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics , 2021, Experimental Neurology.

[5]  C. Stove,et al.  Synthesis and Functional Characterization of 2-(2,5-Dimethoxyphenyl)-N-(2-fluorobenzyl)ethanamine (25H-NBF) Positional Isomers. , 2021, ACS chemical neuroscience.

[6]  Renjith Thomas,et al.  Structure, conformational dynamics, quantum mechanical studies and potential biological activity analysis of multiple sclerosis medicine ozanimod , 2021 .

[7]  C. Stove,et al.  Serotonin 2A Receptor (5-HT2AR) Activation by 25H-NBOMe Positional Isomers: In Vitro Functional Evaluation and Molecular Docking. , 2021, ACS pharmacology & translational science.

[8]  R. Santillán,et al.  Synthesis, characterization and in silico screening of potential biological activity of 17α-ethynyl-3β, 17β, 19-trihydroxyandrost-5-en acetylated derivatives , 2021, Journal of Molecular Structure.

[9]  Ryan Y. Wong,et al.  Differential effects of ethanol on behavior and GABAA receptor expression in adult zebrafish (Danio rerio) with alternative stress coping styles , 2020, Scientific Reports.

[10]  S. Strungaru,et al.  Which Zebrafish Strains Are More Suitable to Perform Behavioral Studies? A Comprehensive Comparison by Phenomic Approach , 2020, Biology.

[11]  V. Flockerzi,et al.  How to Study the Metabolism of New Psychoactive Substances for the Purpose of Toxicological Screenings—A Follow-Up Study Comparing Pooled Human Liver S9, HepaRG Cells, and Zebrafish Larvae , 2020, Frontiers in Chemistry.

[12]  A. Kalueff,et al.  Sex differences in behavior and neuropharmacology of zebrafish , 2020, The European journal of neuroscience.

[13]  R. Gainetdinov,et al.  Effects of acute and chronic arecoline in adult zebrafish: Anxiolytic-like activity, elevated brain monoamines and the potential role of microglia , 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[14]  A. Lebedev,et al.  Synthesis, determination of analytical characteristics and differentiation of positional isomers in the series of N-(2-methoxybenzyl)-2-(dimethoxyphenyl)ethanamine by means of chromatography-mass spectrometry. , 2020, Drug testing and analysis.

[15]  M. Liechti,et al.  Designer drugs: mechanism of action and adverse effects , 2020, Archives of Toxicology.

[16]  A. Kalueff,et al.  Behavioral and physiological effects of acute and chronic kava exposure in adult zebrafish. , 2020, Neurotoxicology and teratology.

[17]  E. Vermetten,et al.  Reviewing the Potential of Psychedelics for the Treatment of PTSD , 2020, The international journal of neuropsychopharmacology.

[18]  J. Zawilska,et al.  NBOMes–Highly Potent and Toxic Alternatives of LSD , 2020, Frontiers in Neuroscience.

[19]  A. Kalueff,et al.  Understanding neurobehavioral effects of acute and chronic stress in zebrafish , 2020, Stress.

[20]  A. Kalueff,et al.  High-glucose/high-cholesterol diet in zebrafish evokes diabetic and affective pathogenesis: The role of peripheral and central inflammation, microglia and apoptosis , 2020, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[21]  M. A. De Luca,et al.  Neurochemical and Behavioral Profiling in Male and Female Rats of the Psychedelic Agent 25I-NBOMe , 2019, Front. Pharmacol..

[22]  In Soo Ryu,et al.  25B‐NBOMe, a novel N‐2‐methoxybenzyl‐phenethylamine (NBOMe) derivative, may induce rewarding and reinforcing effects via a dopaminergic mechanism: Evidence of abuse potential , 2019, Addiction biology.

[23]  R. Irizarry.  ggplot2 , 2019, Introduction to Data Science.

[24]  Hyoung‐Chun Kim,et al.  A novel designer drug, 25N-NBOMe, exhibits abuse potential via the dopaminergic system in rodents , 2019, Brain Research Bulletin.

[25]  P. De Deurwaerdère,et al.  Effect of the 5-HT2C Receptor Agonist WAY-163909 on Serotonin and Dopamine Metabolism across the Rat Brain: A Quantitative and Qualitative Neurochemical Study , 2019, International journal of molecular sciences.

[26]  A. Kalueff,et al.  The role of intraspecies variation in fish neurobehavioral and neuropharmacological phenotypes in aquatic models. , 2019, Aquatic toxicology.

[27]  A. Kalueff,et al.  Opioid Neurobiology, Neurogenetics and Neuropharmacology in Zebrafish , 2019, Neuroscience.

[28]  A. Wach,et al.  Hallucinogen-Like Action of the Novel Designer Drug 25I-NBOMe and Its Effect on Cortical Neurotransmitters in Rats , 2019, Neurotoxicity Research.

[29]  A. Kalueff,et al.  The evolutionarily conserved role of melatonin in CNS disorders and behavioral regulation: Translational lessons from zebrafish , 2019, Neuroscience & Biobehavioral Reviews.

[30]  J. Woolley,et al.  Psychedelic-Assisted Group Therapy: A Systematic Review , 2019, Journal of psychoactive drugs.

[31]  A. Kalueff,et al.  Acute behavioral effects of deliriant hallucinogens atropine and scopolamine in adult zebrafish , 2019, Behavioural Brain Research.

[32]  A. Janowsky,et al.  Neurochemical pharmacology of psychoactive substituted N‐benzylphenethylamines: High potency agonists at 5‐HT2A receptors , 2018, Biochemical pharmacology.

[33]  E. Chesler,et al.  Comparing phenotypic variation between inbred and outbred mice , 2018, Nature Methods.

[34]  K. Rice,et al.  Comparative neuropharmacology of N-(2-methoxybenzyl)-2,5-dimethoxyphenethylamine (NBOMe) hallucinogens and their 2C counterparts in male rats , 2018, Neuropharmacology.

[35]  A. Kalueff,et al.  Zebrafish models for personalized psychiatry: Insights from individual, strain and sex differences, and modeling gene x environment interactions , 2018, Journal of neuroscience research.

[36]  P. Musienko,et al.  Zebrafish models relevant to studying central opioid and endocannabinoid systems , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[37]  R. Gainetdinov,et al.  The Effects of Chronic Amitriptyline on Zebrafish Behavior and Monoamine Neurochemistry , 2018, Neurochemical Research.

[38]  Christopher Rex,et al.  Modeling consequences of prolonged strong unpredictable stress in zebrafish: Complex effects on behavior and physiology , 2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[39]  Bernhard Voelkl,et al.  Reproducibility of preclinical animal research improves with heterogeneity of study samples , 2018, PLoS biology.

[40]  D. Nutt,et al.  Psychiatry & the psychedelic drugs. Past, present & future , 2017, Neuropharmacology.

[41]  Ryan S. Renslow,et al.  Optimizing colormaps with consideration for color vision deficiency to enable accurate interpretation of scientific data , 2017, PloS one.

[42]  A. Kalueff,et al.  Adult zebrafish in CNS disease modeling: a tank that's half-full, not half-empty, and still filling , 2017, Lab Animal.

[43]  B. Leonard,et al.  Animal inflammation-based models of depression and their application to drug discovery , 2017, Expert opinion on drug discovery.

[44]  A. Kalueff,et al.  Zebrafish models in neuropsychopharmacology and CNS drug discovery , 2017, British journal of pharmacology.

[45]  A. Kalueff,et al.  Acute effects of amitriptyline on adult zebrafish: Potential relevance to antidepressant drug screening and modeling human toxidromes. , 2017, Neurotoxicology and teratology.

[46]  Raphaël Millière,et al.  Looking for the Self: Phenomenology, Neurophysiology and Philosophical Significance of Drug-induced Ego Dissolution , 2017, Frontiers in human neuroscience.

[47]  Robin L Carhart-Harris,et al.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future , 2017, Neuropsychopharmacology.

[48]  Y. Hayashi,et al.  The psychoactive drug 25B-NBOMe recapitulates rhabdomyolysis in zebrafish larvae , 2017, Forensic Toxicology.

[49]  P. Deurwaerdère,et al.  Correlative analysis of dopaminergic and serotonergic metabolism across the brain to study monoaminergic function and interaction , 2017, Journal of Neuroscience Methods.

[50]  Oliver Koch,et al.  What Can We Learn from Bioactivity Data? Chemoinformatics Tools and Applications in Chemical Biology Research. , 2017, ACS chemical biology.

[51]  Evan J. Kyzar,et al.  Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models. , 2016, Zebrafish.

[52]  G. Knudsen,et al.  Low frontal serotonin 2A receptor binding is a state marker for schizophrenia? , 2016, European Neuropsychopharmacology.

[53]  John Chilton,et al.  The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update , 2016, Nucleic Acids Res..

[54]  Jorge Cadima,et al.  Principal component analysis: a review and recent developments , 2016, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[55]  B. Jensen,et al.  Case series: toxicity from 25B-NBOMe – a cluster of N-bomb cases , 2016, Clinical toxicology.

[56]  M. Liechti,et al.  Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs) , 2015, Neuropharmacology.

[57]  M. Farré,et al.  Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions , 2015, BioMed research international.

[58]  R. Stackman,et al.  The role of serotonin 5-HT2A receptors in memory and cognition , 2015, Front. Pharmacol..

[59]  A. Stewart,et al.  Building Zebrafish Neurobehavioral Phenomics: Effects of Common Environmental Factors on Anxiety and Locomotor Activity. , 2015, Zebrafish.

[60]  Kevin G Shanks,et al.  Fatal Intoxications with 25B-NBOMe and 25I-NBOMe in Indiana During 2014. , 2015, Journal of analytical toxicology.

[61]  P. Dargan,et al.  Prevalence of use and acute toxicity associated with the use of NBOMe drugs , 2015, Clinical toxicology.

[62]  I. Papoutsis,et al.  2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and legislative aspects , 2015, Drug and chemical toxicology.

[63]  D. E. Nichols,et al.  N-Benzyl-5-methoxytryptamines as Potent Serotonin 5-HT2 Receptor Family Agonists and Comparison with a Series of Phenethylamine Analogues , 2014, ACS chemical neuroscience.

[64]  M. Girabent-Farrés,et al.  Methodological Quality and Reporting of Generalized Linear Mixed Models in Clinical Medicine (2000–2012): A Systematic Review , 2014, PloS one.

[65]  A. Stewart,et al.  Aquatic toxicology of fluoxetine: understanding the knowns and the unknowns. , 2014, Aquatic toxicology.

[66]  Matthew O. Parker,et al.  Molecular psychiatry of zebrafish , 2014, Molecular Psychiatry.

[67]  Joji Suzuki,et al.  “My Friend Said it was Good LSD”: A Suicide Attempt Following Analytically Confirmed 25I-NBOMe Ingestion , 2014, Journal of psychoactive drugs.

[68]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[69]  G. Martinotti,et al.  25C-NBOMe: Preliminary Data on Pharmacology, Psychoactive Effects, and Toxicity of a New Potent and Dangerous Hallucinogenic Drug , 2014, BioMed research international.

[70]  T. Passie,et al.  Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases , 2014, The Journal of nervous and mental disease.

[71]  Vladimir Poroikov,et al.  Prediction of the Biological Activity Spectra of Organic Compounds Using the Pass Online Web Resource , 2014, Chemistry of Heterocyclic Compounds.

[72]  Robert Gerlai,et al.  Zebrafish models for translational neuroscience research: from tank to bedside , 2014, Trends in Neurosciences.

[73]  M. Geyer,et al.  Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response , 2014, Neuropharmacology.

[74]  A. Stewart,et al.  The behavioral effects of acute Δ9-tetrahydrocannabinol and heroin (diacetylmorphine) exposure in adult zebrafish , 2014, Brain Research.

[75]  Gregory L. Stuart,et al.  The NBOMe series: a novel, dangerous group of hallucinogenic drugs. , 2013, Journal of studies on alcohol and drugs.

[76]  A. Stewart,et al.  Perspectives on zebrafish models of hallucinogenic drugs and related psychotropic compounds. , 2013, ACS chemical neuroscience.

[77]  J Radua,et al.  The impact of CACNA1C allelic variation on effective connectivity during emotional processing in bipolar disorder , 2013, Molecular Psychiatry.

[78]  Stephan C F Neuhauss,et al.  Towards a comprehensive catalog of zebrafish behavior 1.0 and beyond. , 2013, Zebrafish.

[79]  M. Geyer,et al.  Characterization of the head-twitch response induced by hallucinogens in mice , 2013, Psychopharmacology.

[80]  D. E. Nichols,et al.  Extensive rigid analogue design maps the binding conformation of potent N-benzylphenethylamine 5-HT2A serotonin receptor agonist ligands. , 2013, ACS chemical neuroscience.

[81]  Siddharth Gaikwad,et al.  Unique and potent effects of acute ibogaine on zebrafish: The developing utility of novel aquatic models for hallucinogenic drug research , 2013, Behavioural Brain Research.

[82]  D. Morgan,et al.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model. , 2012, Drug testing and analysis.

[83]  S. Watts,et al.  Fundamental approaches to the study of zebrafish nutrition. , 2012, ILAR journal.

[84]  Evan J. Kyzar,et al.  Effects of hallucinogenic agents mescaline and phencyclidine on zebrafish behavior and physiology , 2012, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[85]  Siddharth Gaikwad,et al.  Modeling anxiety using adult zebrafish: A conceptual review , 2012, Neuropharmacology.

[86]  Siddharth Gaikwad,et al.  Behavioral and physiological effects of acute ketamine exposure in adult zebrafish. , 2011, Neurotoxicology and teratology.

[87]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[88]  Adam L. Halberstadt,et al.  Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens , 2011, Neuropharmacology.

[89]  Evan J. Kyzar,et al.  Behavioral effects of MDMA (‘ecstasy’) on adult zebrafish , 2011, Behavioural pharmacology.

[90]  Anders Ettrup,et al.  Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[91]  David Curtis,et al.  Case–case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes , 2011, Psychiatric genetics.

[92]  G. Torres,et al.  A behavioral and molecular analysis of ketamine in zebrafish , 2011, Synapse.

[93]  C. Grob,et al.  Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. , 2011, Archives of general psychiatry.

[94]  Siddharth Gaikwad,et al.  Characterization of behavioral and endocrine effects of LSD on zebrafish , 2010, Behavioural Brain Research.

[95]  Mi-Ok Kim,et al.  Statistical issues in longitudinal data analysis for treatment efficacy studies in the biomedical sciences. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[96]  Michael Kometer,et al.  The neurobiology of psychedelic drugs: implications for the treatment of mood disorders , 2010, Nature Reviews Neuroscience.

[97]  A. Stewart,et al.  Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish , 2010, Brain Research.

[98]  M C O'Donovan,et al.  The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia , 2009, Molecular Psychiatry.

[99]  J. F. Alder,et al.  The Henry reaction: spectroscopic studies of nitrile and hydroxylamine by-products formed during synthesis of psychoactive phenylalkylamines , 2008 .

[100]  S. Gabriel,et al.  Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder , 2008, Nature Genetics.

[101]  A. Lewin,et al.  High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. , 2008, Bioorganic & medicinal chemistry.

[102]  Matthew W. Johnson,et al.  Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later , 2008, Journal of psychopharmacology.

[103]  P. Moya,et al.  Functional Selectivity of Hallucinogenic Phenethylamine and Phenylisopropylamine Derivatives at Human 5-Hydroxytryptamine (5-HT)2A and 5-HT2C Receptors , 2007, Journal of Pharmacology and Experimental Therapeutics.

[104]  Stuart C. Sealfon,et al.  Hallucinogens Recruit Specific Cortical 5-HT2A Receptor-Mediated Signaling Pathways to Affect Behavior , 2007, Neuron.

[105]  Caleb F. Davis,et al.  Stargazin and Other Transmembrane AMPA Receptor Regulating Proteins Interact with Synaptic Scaffolding Protein MAGI-2 in Brain , 2006, The Journal of Neuroscience.

[106]  A. Khuri,et al.  Generalized Linear Models , 2005 .

[107]  David R. Anderson,et al.  Multimodel Inference , 2004 .

[108]  Mark D. Berry,et al.  Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators , 2004, Journal of neurochemistry.

[109]  J. Huidobro‐Toro,et al.  4‐Bromo‐2,5‐dimethoxyphenethylamine (2C‐B) and structurally related phenylethylamines are potent 5‐HT2A receptor antagonists in Xenopus laevis oocytes , 2004, British journal of pharmacology.

[110]  Dane M. Chetkovich,et al.  Stargazin regulates synaptic targeting of AMPA receptors by two distinct mechanisms , 2000, Nature.

[111]  V. Vinogradova,et al.  Synthesis based on β-phenylethylamines. IV. Synthesis and antiarrhythmic activity of substituted phenylalkylamines and N-benzyltetrahydroisoquinolines , 1993, Chemistry of Natural Compounds.

[112]  B. Jacobs,et al.  Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. , 1976, European journal of pharmacology.

[113]  H. Akaike.  A new look at the statistical model identification , 1974 .

[114]  J. S. Buck,et al.  Antifibrillatory Agents. The Preparation of Some N-Benzyl-N-methylphenethylamines , 1949 .

[115]  Adwitiya Chaudhuri,et al.  Zebrafish neurobehavioral phenomics for aquatic neuropharmacology and toxicology research. , 2016, Aquatic toxicology.

[116]  Matthew W. Johnson,et al.  Can psychedelic compounds play a part in drug dependence therapy? , 2015, The British journal of psychiatry : the journal of mental science.

[117]  Adrià Cereto-Massagué,et al.  Molecular fingerprint similarity search in virtual screening. , 2015, Methods.

[118]  J. Cachat,et al.  Zebrafish Neurobehavioral Protocols , 2011, Neuromethods.

[119]  L. L. Carvalho,et al.  An expeditious and consistent procedure for tetrahydrofuran (THF) drying and deoxygenation by the still apparatus , 2009 .

[120]  A. Kalueff,et al.  The Aquila Digital Community The Aquila Digital Community Comparative Analyses of Zebrafish Anxiety-Like Behavior Using Comparative Analyses of Zebrafish Anxiety-Like Behavior Using Conflict-Based Novelty Tests Conflict-Based Novelty Tests , 2022 .